NP
CHRONICLES
Clinical Education for NP Students & New Graduates
Creatine
and the Immune System: What a New Dendritic Cell Study Means for Cancer Care
Research
Spotlight | Oncology & Immunology |
Board-Relevant Physiology
Ask most people what creatine is
for, and you'll get the same answer: bigger lifts, more muscle, better gym
performance. That reputation is well earned — creatine is one of the most
studied and safest performance supplements available. But a growing body of
research is pointing to a second life for this humble metabolite, one that has
nothing to do with the squat rack and everything to do with how the immune
system fights cancer.
A study published in iScience in
April 2026 by Kang, Elsten-Brown, Wang, and colleagues at UCLA adds an
important piece to that story. The researchers show that dendritic cells — the
immune system's professional “antigen presenters” — rely on creatine to power
their activation, and that supplementing creatine can make dendritic cells
better at rallying T cells against tumors. For NPs working in oncology, primary
care, or integrative settings, this is worth understanding, both for the
mechanism and for the practical conversations it's likely to generate with
patients.
A Quick Refresher: What
Dendritic Cells Actually Do
Dendritic cells (DCs) are the
immune system's scouts and messengers. They sit in tissues — including tumors —
waiting to detect danger signals. Once activated, they capture antigens,
migrate to lymph nodes, and present those antigens to T cells, essentially
teaching the adaptive immune system what to attack. Without well-activated DCs,
T cells never get the briefing they need to mount an effective antitumor
response.
Tumors know this, and part of
how cancers evade the immune system is by starving or disabling the DCs sitting
inside them. A tumor microenvironment that's short on nutrients and long on
metabolic stress tends to produce sluggish, poorly activated DCs — and sluggish
DCs mean an under-primed T cell army.
What the Study Found
The research team started by
looking at gene expression in dendritic cells pulled from mouse melanoma tumors
and compared them to DCs from the spleen. One gene stood out: the creatine
transporter, CrT (also known as SLC6A8), was markedly upregulated in the
tumor-dwelling DCs. The same transporter also increased sharply when lab-grown
DCs were stimulated with a bacterial signal (LPS), the kind of “danger cue”
that triggers DC activation.
That pattern — a transporter
that goes up specifically when a cell is activated or under metabolic pressure
— is a strong hint that creatine uptake matters for DC function. The team then
tested that hint directly using three complementary approaches.
1. Knock out the creatine
transporter, and DCs struggle.
•
Dendritic
cells grown from CrT-knockout mice showed sharply reduced survival after
activation.
•
They
expressed lower levels of activation markers CD86 and MHC-II (I-Ab).
•
They
produced less TNF-α and IL-6, and were markedly worse at driving proliferation
and cytokine output in antigen-specific T cells co-cultured alongside them.
•
When
these knockout DCs were injected into mice and the animals' T cell recall
response was tested two weeks later, the response was measurably weaker —
confirming the defect held up in a living animal, not just a dish.
2. Add creatine, and DCs do
better.
•
Creatine
supplementation improved survival of activated dendritic cells.
•
It
increased expression of the same activation markers (CD86, MHC-II) and boosted
proinflammatory cytokine output (IL-1β, IL-6, TNF-α).
•
The
effect wasn't limited to one type of activation signal — it held up whether DCs
were stimulated through TLR4 (LPS) or TLR3 (poly I:C) pathways, suggesting a
fairly general effect on DC activation rather than a quirk of one signaling
route.
3. The mechanism traces back to
ATP.
Using mass spectrometry, the
researchers showed that creatine-supplemented DCs held higher intracellular ATP
and lower AMP/ADP — in other words, better-buffered energy reserves. That
mattered because DC activation runs through energy-hungry signaling cascades,
particularly NF-κB. When creatine (or ATP itself) was added, NF-κB signaling
ramped up; when the creatine transporter was blocked or deleted, NF-κB
signaling dropped off. The takeaway: creatine isn't acting as a magic immune
signal on its own — it's topping off the ATP tank that inflammatory signaling
pathways draw from.
From the Dish to the Mouse to
(Possibly) the Clinic
The in vitro findings held up in
living animals. In a mouse melanoma model, daily creatine injections slowed
tumor growth and increased the number and activation of a particularly potent
DC subset (cDC1s) inside the tumor. Single-cell sequencing of tumor-infiltrating
immune cells showed creatine-treated dendritic cells turning up inflammatory
and antigen-presentation genes while turning down glycolysis — a metabolic
signature consistent with DCs shifting from “conserve energy” mode into “get to
work” mode.
Encouragingly, the human data
pointed the same direction. Monocyte-derived dendritic cells grown from healthy
donor blood also upregulated the creatine transporter upon stimulation, and
creatine supplementation boosted their inflammatory cytokine output and their
ability to activate antigen-specific T cells targeting NY-ESO-1, a tumor
antigen expressed across many cancer types.
|
CLINICAL BOTTOM LINE Creatine appears to help fuel
dendritic cell activation by preserving intracellular ATP, which in turn
sustains the inflammatory signaling (chiefly NF-κB) that dendritic cells need
to prime T cells against tumors. In mouse models, creatine supplementation
slowed tumor growth and improved dendritic cell activity within tumors. This
is preclinical, mechanistic work — not a clinical recommendation — but it
strengthens a pattern already seen with creatine's effects on T cells and
macrophages in cancer immunity. |
Why This Fits a Bigger Pattern
This isn't creatine's first
appearance in the cancer immunology literature. Earlier work from some of the
same investigators found that creatine uptake directly boosts antitumor CD8 T
cell responses, and separate research has linked creatine to proinflammatory
(M1-like) polarization of tumor-associated macrophages. Taken together, three
major arms of the antitumor immune response — T cells, macrophages, and now
dendritic cells — all appear to lean on the same creatine/ATP buffering system
when they're asked to do energetically demanding work.
There's also an epidemiologic
thread worth mentioning: a retrospective analysis of NHANES data spanning
roughly a decade found that higher dietary creatine intake was associated with
a lower incidence of cancer. Association isn't causation, and dietary pattern
data is notoriously confounded, but it's a data point that lines up
directionally with the mechanistic work.
A nuance patients (and
clinicians) should know
|
NUANCE TO FLAG Creatine's relationship with
cancer is not one-directional. Several studies cited in this same paper note
that malignant cells can co-opt creatine metabolism to fuel their own
metastasis and progression, and that blocking creatine transport or creatine
kinase has slowed tumor growth in some prostate and colon cancer models. In
other words, the same energy-buffering trick that helps immune cells work
harder may, in a different cellular context, help cancer cells work harder
too. This is exactly why “creatine is good for the immune system” cannot be
flattened into “patients with cancer should take creatine” without
qualification. |
What This Means for Practice —
For Now
It's worth being precise about
what this study does and doesn't support, especially given how often patients
arrive already primed by supplement marketing and social media health claims.
•
This
is preclinical (mouse and in vitro human cell) research. There is no clinical
trial yet testing creatine supplementation as an adjunct cancer immunotherapy
in patients.
•
The
antitumor benefit was shown in a single mouse melanoma model. The authors
themselves note this as a limitation and call for testing across more
physiologically relevant tumor models.
•
Creatine's
documented benefits in oncology so far are strongest for supportive care —
there is existing evidence that creatine can help preserve muscle mass and body
weight in cancer-associated cachexia, and some data suggesting it may blunt
doxorubicin-related cardiotoxicity.
•
Creatine
has a well-established long-term safety profile in the general population,
which is part of why the authors argue it could move to clinical trials
relatively quickly — but “could move to trials” is not the same as “is ready
for clinical use” in oncology, particularly given the tumor-promoting data
mentioned above.
•
Patients
on active cancer treatment who ask about creatine supplementation should be
directed to discuss it with their oncology team before starting, given the
mixed tumor-intrinsic data and the lack of trials in this specific context.
The Physiology Worth Remembering
For board review and patient
teaching alike, the core mechanism is a nice illustration of basic
bioenergetics applied to immunology:
•
Creatine
enters cells via the creatine transporter (CrT/SLC6A8).
•
Creatine
kinase converts creatine to phosphocreatine, which acts as a rapidly mobilized
energy reserve.
•
When
ATP is consumed, phosphocreatine donates a phosphate group back to ADP, quickly
regenerating ATP — the same creatine kinase/phosphocreatine shuttle that powers
muscle during short bursts of intense activity.
•
Activated
immune cells, it turns out, tap the same energy-buffering system to sustain the
signaling cascades (like NF-κB) that drive inflammatory gene expression.
It's the same biochemistry
bodybuilders have relied on for decades — just running inside a dendritic cell
instead of a bicep.
Bottom Line for Your Next
Patient Conversation
If a patient with cancer asks
about creatine supplementation after reading about “immune-boosting” research,
this is a reasonable framework: the mechanistic and preclinical case for
creatine supporting antitumor immunity is real and growing, but it is not yet
clinical evidence, and creatine's effects on tumor cells themselves are
context-dependent and not uniformly favorable. Encourage patients to loop in
their oncology team, and reserve enthusiasm for the supportive-care indications
(cachexia, possibly cardioprotection during certain chemotherapy regimens)
where the evidence base is more mature.
References
Kang, E., Elsten-Brown, J.,
Wang, Y.-C., et al. (2026). Creatine uptake promotes dendritic cell activation
and enhances antitumor immunity. iScience, 29, 115436.
https://doi.org/10.1016/j.isci.2026.115436
Di Biase,
S., Ma, X., Wang, X., et al. (2019). Creatine uptake regulates CD8 T cell antitumor immunity.
J Exp Med, 216, 2869–2882.
Peng, Z., & Saito, S.
(2023). Creatine supplementation enhances anti-tumor immunity by promoting ATP
production in macrophages. Front Immunol, 14, 1176956.
Jiang, J.,
Zhao, H., Chen, J., et al. (2024). The association between dietary creatine intake and
cancer in U.S. adults: insights from NHANES 2007–2018. Front Nutr,
11, 1460057.
Wei, L.,
Wang, R., Lin, K., et al. (2022).
Creatine modulates cellular energy metabolism and protects against cancer
cachexia-associated muscle wasting. Front Pharmacol, 13, 1086662.
